AU2003297012A1 - Transgenic mice expressing human cd20 and/or cd16 - Google Patents

Transgenic mice expressing human cd20 and/or cd16 Download PDF

Info

Publication number
AU2003297012A1
AU2003297012A1 AU2003297012A AU2003297012A AU2003297012A1 AU 2003297012 A1 AU2003297012 A1 AU 2003297012A1 AU 2003297012 A AU2003297012 A AU 2003297012A AU 2003297012 A AU2003297012 A AU 2003297012A AU 2003297012 A1 AU2003297012 A1 AU 2003297012A1
Authority
AU
Australia
Prior art keywords
human
cells
animal
agent
transgenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003297012A
Other languages
English (en)
Inventor
Andrew Chee-Yuen Chan
Qian Gong
Flavius Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2003297012A1 publication Critical patent/AU2003297012A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
AU2003297012A 2002-12-16 2003-12-11 Transgenic mice expressing human cd20 and/or cd16 Abandoned AU2003297012A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43411502P 2002-12-16 2002-12-16
US60/434,115 2002-12-16
US47648103P 2003-06-05 2003-06-05
US60/476,481 2003-06-05
PCT/US2003/039686 WO2004060052A2 (en) 2002-12-16 2003-12-11 Transgenic mice expressing human cd20 and/or cd16

Publications (1)

Publication Number Publication Date
AU2003297012A1 true AU2003297012A1 (en) 2004-07-29

Family

ID=32717770

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003297012A Abandoned AU2003297012A1 (en) 2002-12-16 2003-12-11 Transgenic mice expressing human cd20 and/or cd16
AU2003297023A Abandoned AU2003297023A1 (en) 2002-12-16 2003-12-11 Transgenic mice expressing human cd20

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003297023A Abandoned AU2003297023A1 (en) 2002-12-16 2003-12-11 Transgenic mice expressing human cd20

Country Status (9)

Country Link
US (2) US7402728B2 (https=)
EP (2) EP1573313A4 (https=)
JP (2) JP2006517096A (https=)
KR (2) KR20050084317A (https=)
AT (1) ATE401787T1 (https=)
AU (2) AU2003297012A1 (https=)
CA (2) CA2507882A1 (https=)
DE (1) DE60322426D1 (https=)
WO (2) WO2004060052A2 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
KR100666607B1 (ko) * 2004-11-03 2007-01-09 재단법인서울대학교산학협력재단 이종의 ｃｄ４ ｔ-세포 생산방법 및 이종의 ｃｄ４ｔ-세포를 생산하는 동물모델
WO2006049439A1 (en) * 2004-11-03 2006-05-11 Dinona Inc. Method of producing xenogenic cd4 t-cell and animal model producing xenogenic cd4 t-cell
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
EP2245055A2 (en) * 2008-01-31 2010-11-03 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
MY169771A (en) 2008-04-23 2019-05-15 Univ Leland Stanford Junior Systems, methods and compositions for optical stimulation of target cells
EP2303405A4 (en) 2008-06-17 2017-12-27 The Board of Trustees of the Leland Stanford Junior University Apparatus and methods for controlling cellular development
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
KR101065066B1 (ko) * 2008-10-23 2011-09-15 사회복지법인 삼성생명공익재단 태아 흉선 및 간 조직과 제대혈 유래 조혈모 세포의 동시 이식에 기반한 인간화 ｎｏｇ 마우스 모델 및 그의 제조 방법
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
PT2485583T (pt) 2009-10-06 2016-09-22 Univ Yale Ratinhos geneticamente modificados e enxerto
US8883496B2 (en) 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice
PL3498730T3 (pl) 2009-12-21 2026-04-07 Regeneron Pharmaceuticals, Inc. Humanizowane myszy fc gamma r
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
WO2012061741A2 (en) * 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University. Control and characterization of psychotic states
CN106422081B (zh) 2010-11-05 2019-06-21 斯坦福大学托管董事会 用于光遗传学方法的光的上转换
WO2012061679A2 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
CN106376525A (zh) 2010-11-05 2017-02-08 斯坦福大学托管董事会 记忆功能的控制和表征
ES2684307T3 (es) 2010-11-05 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University Proteínas estabilizadas de tipo opsina de función escalonada y métodos de uso de las mismas
CN106106368A (zh) 2010-11-05 2016-11-16 斯坦福大学托管董事会 光控cns功能障碍
AU2011323235B2 (en) 2010-11-05 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of reward-related behaviors
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
MX350385B (es) 2011-02-15 2017-09-04 Regeneron Pharma Ratones de m-csf humanizada.
CA2859364C (en) 2011-12-16 2019-05-07 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
CA2860770A1 (en) * 2012-01-13 2013-07-18 Advanced Genomic Technology, Llc Transgenic non-human animal model for accelerated aging and/or age-rela ted symptom, and use thereof
EP3205374B1 (en) 2012-02-21 2019-03-27 The Board of Trustees of The Leland Stanford Junior University Compositions for treating neurogenic disorders of the pelvic floor
IN2015DN02032A (https=) 2012-09-07 2015-08-14 Univ Yale
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
US9510569B2 (en) * 2013-03-13 2016-12-06 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation
JP6594854B2 (ja) 2013-03-15 2019-10-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 行動状態の光遺伝学的制御方法
AU2014260101B2 (en) 2013-04-29 2018-07-26 Humboldt-Universitat Zu Berlin Devices, systems and methods for optogenetic modulation of action potentials in target cells
EP3003022B1 (en) 2013-06-04 2017-11-22 Virginia Commonwealth University Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics
EP3004872B1 (en) 2013-06-04 2017-10-18 Virginia Commonwealth University Mda-9/syntenin promoter to image and treat metastatic cancer cells
US9781909B2 (en) * 2013-07-17 2017-10-10 University Of Manitoba Mito-Ob: a transgenic mouse model for obesity
EP3033427A4 (en) 2013-08-14 2017-05-31 The Board Of Trustees Of The University Of the Leland Stanford Junior University Compositions and methods for controlling pain
HUE051088T2 (hu) 2014-04-08 2021-03-01 Regeneron Pharma Humanizált FC-gamma receptorokkal rendelkezõ nem humán élõlények
SG10202002187WA (en) 2014-05-19 2020-04-29 Regeneron Pharma Genetically modified non-human animals expressing human epo
AU2015289644A1 (en) * 2014-07-15 2017-02-02 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
HUE052606T2 (hu) * 2014-12-09 2021-05-28 Regeneron Pharma Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
KR102658190B1 (ko) 2015-04-13 2024-04-17 리제너론 파마슈티칼스 인코포레이티드 인간화된 sirpa-il15 녹인 마우스 및 이의 이용 방법
CA2984413A1 (en) * 2015-04-30 2016-11-03 Institute Of Immunology Co., Ltd. Transgenic non-human animal expressing human specific molecule and human fc.gamma. receptor family
WO2016196666A2 (en) * 2015-06-01 2016-12-08 Bloodworks Mice with modified glucose-6-phosphate dehydrogenase (g6pd) and uses thereof
JP6961494B2 (ja) * 2015-06-10 2021-11-05 フイルメニツヒ ソシエテ アノニムFirmenich Sa 匂い物質および芳香の受容体をスクリーニングするための細胞株
WO2016209654A1 (en) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
EP3322801A1 (en) 2015-07-15 2018-05-23 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US11963520B2 (en) * 2016-01-19 2024-04-23 Celgene Corporation Transgenic mouse expressing human cereblon
LU92964B1 (en) * 2016-01-28 2017-08-07 Univ Luxembourg Means and methods for selecting transformed cells
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
JP7504030B2 (ja) 2018-06-13 2024-06-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 進行性骨化性線維異形成症のげっ歯類モデル
WO2022262808A1 (en) * 2021-06-16 2022-12-22 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd20 genes
JP2024527276A (ja) * 2021-06-22 2024-07-24 フジフイルム アーバイン サイエンティフィック， インコーポレイテッド トランスジェニックマウス系統の方法および使用
KR20240102971A (ko) 2021-11-16 2024-07-03 제넨테크, 인크. 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
AU1213695A (en) 1993-12-01 1995-06-19 United States Of America, As Represented By The Secretary, Department Of Health And Human Services (in vivo) assays for inhibitors of ige mediated allergic responses
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
JP2003529361A (ja) 2000-03-30 2003-10-07 アムジェン インコーポレイテッド ＣＤ２０／ＩｇＥレセプター様分子およびその使用
US20020128448A1 (en) * 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
AU2002251692A1 (en) 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
US20050177884A1 (en) * 2001-11-15 2005-08-11 Kirin Beer Kabushiki Kaisha Chimeric nonhuman animal

Also Published As

Publication number Publication date
JP2006513725A (ja) 2006-04-27
EP1573313A4 (en) 2006-05-17
DE60322426D1 (https=) 2008-09-04
WO2004060053A2 (en) 2004-07-22
CA2507882A1 (en) 2004-07-22
WO2004060053A3 (en) 2005-01-27
AU2003297023A1 (en) 2004-07-29
CA2507880A1 (en) 2004-07-22
US20060218655A1 (en) 2006-09-28
EP1573314A4 (en) 2006-07-26
ATE401787T1 (de) 2008-08-15
EP1573314B1 (en) 2008-07-23
WO2004060052A3 (en) 2004-09-23
EP1573314A2 (en) 2005-09-14
KR20050084317A (ko) 2005-08-26
KR20050084318A (ko) 2005-08-26
WO2004060052A2 (en) 2004-07-22
EP1573313A2 (en) 2005-09-14
US20060179501A1 (en) 2006-08-10
JP2006517096A (ja) 2006-07-20
US7402728B2 (en) 2008-07-22

Similar Documents

Publication Publication Date Title
US7402728B2 (en) Transgenic mice expressing human CD20 and/or CD16
US10945418B2 (en) Genetically modified non-human animal with human or chimeric PD-L1
US11317611B2 (en) Genetically modified non-human animal with human or chimeric PD-L1
US11071290B2 (en) Genetically modified non-human animal with human or chimeric CTLA-4
US11497198B2 (en) Genetically modified mice expressing humanized CD40
US11505806B2 (en) Genetically modified non-human animal with human or chimeric OX40
US20190352666A1 (en) Genetically Modified Non-Human Animal With Human Or Chimeric OX40
WO2018041121A1 (en) Genetically modified non-human animal with human or chimeric ctla-4
EP4706388A2 (en) Low affinity fc gamma r deficient mice
CA2294604A1 (en) Transgenic animals expressing human fc receptors
CN1751236A (zh) 表达人cd20的转基因小鼠
US10945419B2 (en) Genetically modified non-human animal with human or chimeric GITR
WO2019072241A1 (en) NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
WO2018233607A1 (en) Genetically modified non-human animal with human or chimeric cd40
WO2020103830A1 (en) Genetically modified animal with canine or chimeric pd-1
US10925264B2 (en) Genetically modified non-human animal with human or chimeric LAG-3
EP0853122A2 (en) Transgenic animals lacking functional H2-M molecule
WO2023041035A1 (en) Genetically modified non-human animal with human or chimeric genes
WO2022188871A1 (en) Genetically modified non-human animal with human or chimeric siglec15
WO2024002259A1 (zh) 一种osm、osmr、il31ra和/或il31基因修饰的非人动物
WO2021043290A1 (en) Genetically modified non-human animal with human or chimeric tnfr2
US20250120374A1 (en) Genetically modified non-human animal with human or chimeric genes

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application